arrow
I

Ian McGowan

Department of Medicine
H指数:42
被引数:6,710

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1._

早期接受治疗的HIV-1感染者中,抗病毒治疗分析性中断和HTI疫苗接种后病毒学结局的预测因素。

2025-12-080
OAAI
Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size

Vedolizumab和ART在最近的HIV-1感染中揭示了 α4β7在储层大小中的作用

2024-07-090
OA
Tenofovir Douche as HIV Preexposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics (DREAM 01)
2023-11-294
PRE
A germ-free humanized mouse model shows the contribution of resident microbiota to human-specific pathogen infection
2023-08-1012
OA
Impact of Obefazimod on Viral Persistence, Inflammation, and Immune Activation in People With Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy

奥贝法莫德对接受抑制性抗逆转录病毒治疗的人类免疫缺陷病毒患者的病毒持久性,炎症和免疫激活的影响

2023-07-035
OAAI
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial

HTI疫苗在早期治疗的HIV-1感染中的安全性,免疫原性和对病毒反弹的影响: 一项随机,安慰剂对照的1期试验

2022-10-2733
OA
Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis
AIDS
IF3.1
2021-04-0912
OA
Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV Infection
2020-09-0113
OAAI
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women A Phase 2 Randomized Trial
2017-09-1929
OAAI